Original Semaglutide: Discovery & Research History
Semaglutide (GLP-1 Receptor Agonist) — how it was originally developed, and what it has been studied for since.
How Semaglutide Was Discovered
Semaglutide's story begins over three decades before its FDA approval, with the discovery of GLP-1 itself. In the 1980s, researchers studying the proglucagon gene identified a previously unrecognized hormone fragment, GLP-1(7-37), as the biologically active form of glucagon-like peptide-1 — work that established GLP-1's role in glucose-dependent insulin secretion and set off decades of research into incretin-based diabetes treatment.
Novo Nordisk built on that foundation first with liraglutide (approved 2010), then developed semaglutide using further fatty-acid conjugation and albumin-binding chemistry to extend the molecule's half-life enough for once-weekly dosing rather than daily injection — a critical practical improvement that made the drug class viable for widespread chronic use.
What Semaglutide Has Been Studied For
Semaglutide received FDA approval as Ozempic in 2017 for type 2 diabetes, followed by approval as Wegovy in 2021 for chronic weight management at a higher dose. It remains the reference point every later multi-receptor incretin agonist, including Tirzepatide and Retatrutide, is compared against.
- GLP-1 receptor agonism research
- Comparative incretin-receptor literature
- Reference compound for newer multi-receptor agonists
Read our Weight Loss & Metabolic research overview →
Semaglutide discovery & history questions
Does Semaglutide's research history mean it's approved for a particular use?
No. This page describes how Semaglutide was originally developed and what it has been studied for since — it is historical and educational context, not a claim about current regulatory approval, safety, or legal status anywhere. Semaglutide is a patented prescription pharmaceutical requiring a doctor's prescription, and is not available from KYIN Peptides in any form.
What has Semaglutide been studied for in research?
Semaglutide is studied for GLP-1 receptor agonism in glucose regulation and weight management, and is FDA-approved as the pharmaceuticals Ozempic and Wegovy.
Not available from KYIN Peptides
Semaglutide is a patented, prescription-only pharmaceutical, not a research chemical KYIN sources or sells in any form.